Home » Newsletters » BioWorld Science

BioWorld Science

July 2, 2012

View Archived Issues

New S1P1 receptor ligands presented by researchers at Allergan

Fixed-dose combination drug evaluated in seasonal allergic and chronic rhinitis

Preclinical and phase I results presented for MLN-4924

First-in-human data presented on PD-1-targeted cancer immunotherapy

Otsuka and Kyowa Hakko Kirin to form strategic alliance

FAS-specific antibody for arthritis shows promise in first clinical trial

Multiple early-stage trials of MLN-9708 presented

OSI Pharmaceuticals divulges novel focal adhesion kinase inhibitors

German company discloses new muteins of human lipocalin

Marshall Edwards changes name

Janssen completes acquisition

Somatuline approved in Japan

New agents for hypercholesterolemia designed in Japan

Gilead submits NDA to FDA for AIDS drug

Pfizer patents novel kynurenine aminotransferase II inhibitors

Scientists at Biomay report new hypoallergenic vaccines

Novel antiviral agents developed

GABA(A) receptor modulator improves sleep in human model of insomnia

Laurantis Pharma presents phase I data on eye drop therapy

GSK and Theravance report on phase III COPD trials

Affymetrix expands product portfolio with acquisition

Japanese phase I study of SO-1105 complete

Bristol-Myers Squibb plans acquisition

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 8, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 8, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ASH 2025: New blood cancer therapies trump chemo, older drugs
BioWorld
Targeted therapies and immunotherapies continue to show better results than chemotherapy in investigator-initiated and company-sponsored cancer trials, and newer...